CORCEPT THERAPEUTICS INC CORT

About CORCEPT THERAPEUTICS INC (CORT): stock profile, AI score and financials

CORCEPT THERAPEUTICS INC (CORT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CORT at 57.5/100 on a composite quality score built from its SEC filings, placing it at rank #1,086 of 2,925 stocks — the top half of the AI-ranked universe. CORT scores in the top quartile across earnings quality (84.0), revenue growth (81.2), balance sheet strength (75.4). Areas of concern include institutional flow (37.3) and profitability (38.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CORCEPT THERAPEUTICS INC reports quarterly revenue of $256.1M, net income of $43.0M, an operating margin of 16.1%. Top institutional holders of CORT by reported 13-F value include BlackRock, INGALLS & SNYDER, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. CORT trades on the Nasdaq exchange and files with the SEC under CIK 1088856. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CORT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CORCEPT THERAPEUTICS INC directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1088856 →